In Vitro and In Vivo Antitumor Activity of a Novel pH-Activated Polymeric Drug Delivery System for Doxorubicin

Menglei Huan¹, Bangle Zhang¹, Zenghui Teng¹, Han Cui¹, Jieping Wang², Xinyou Liu², Hui Xia³, Siyuan Zhou¹, Qibing Mei*¹

¹Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China, ²Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, People's Republic of China, ³Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing, People's Republic of China, ⁴Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China

Abstract

Background: Conventional chemotherapy agent such as doxorubicin (DOX) is of limited clinical use because of its inherently low selectivity, which can lead to systemic toxicity in normal healthy tissue.

Methods: A pH stimuli-sensitive conjugate based on polyethylene glycol (PEG) with covalently attachment doxorubicin via hydrazone bond (PEG-hyd-DOX) was prepared for tumor targeting delivery system. While PEG-DOX conjugates via amid bond (PEG-ami-DOX) was synthesized as control.

Results: The synthetic conjugates were confirmed by proton nuclear magnetic resonance (NMR) spectroscopy, the release profile of DOX from PEG-hyd-DOX was acid-labile for the hydrazone linkage between DOX and PEG, led to different intracellular uptake route; intracellular accumulation of PEG-hyd-DOX was higher than PEG-ami-DOX due to its pH-triggered profile, and thereby more cytotoxicity against MCF-7, MDA-MB-231 (breast cancer models) and HepG2 (hepatocellular carcinoma model) cell lines. Following the in vitro results, we xenografted MDA-MB-231 cell onto SCID mice, PEG-hyd-DOX showed stronger antitumor efficacy than free DOX and was tumor-targeting.

Conclusions: Results from these in vivo experiments were consistent with our in vitro results; suggested this pH-triggered PEG-hyd-DOX conjugate could target DOX to tumor tissues and release free drugs by acidic tumor environment, which would be potent in antitumor drug delivery.

Introduction

Conventional chemotherapy agent such as doxorubicin (DOX) is of limited clinical use because of its inherently low selectivity, which can lead to systemic toxicity in normal healthy tissue. This prevents the use of giving high but effective doses for cancer treatment [1–3]. To overcome this problem, several high molecule drug carriers have been designed to deliver antitumor agents passively by targeting tumor tissue or cells using the enhanced permeability and retention effect (EPR effect) with favorable biocompatibility and solubility properties [4]. PEG has been widely used as a drug carrier in many drug design strategies for its low immunogenicity and long circulation time, antitumor agents conjugated to PEG are of great interest because of the passive tumor targeting by EPR effect and slow-released profile, led to a low toxicity, high efficacy and long-acting delivery vehicle [5–6].

Recently, stimuli-sensitive carriers have emerged and attracted great attention for modulating anticancer drug release by appropriate stimulus (temperature, pH etc), which can led to obvious enhanced therapeutic efficacy and low side-effects [7–10]. Considered the mild acidic extracellular microenvironment in tumor tissues and acidic lysosomes or endosomes in cells, pH-sensitive carriers have been ideal for selective release of antitumor agents in tumor tissues and/or within tumor cells. Many strategies have been applied in pH-triggered delivery system [11]. Among the strategies, hydrazone bond (R₁R₂C=NR) has been chosen for its pH-controlled hydrolysis. Polymers linked with hydrazone bond keep stable in physiological condition, once the pH value decrease to 5.0–6.0, the acid-sensitive bond between carrier and drug becomes unstable and then release free drug quickly [12]. Based on this profile, conjugates via hydrazone can bring to a burst of anticancer drug release in acidic organelles after endocytosis by tumor cells, therefore provide a high drug concentration at cellular
level to fulfill better therapeutic efficacy. As reported, even extremely multidrug resistant (MDR) cells can be killed at high drug concentration, so this strategy is also meaningful in MDR cells [13–15].

In this paper, we have designed and covalently synthesized a pH-sensitive PEG-hyd-DOX conjugate for stimuli release of DOX, characterized by NMR and HPLC. The pH-sensitive hydrolysis of PEG-hyd-DOX was confirmed in vitro by HPLC, the higher intracellular accumulation of DOX by PEG-hyd-DOX in tumor cells was determined by HPLC/MS/MS, its probably intracellular route was firstly distributed into acidic organelles and then release free drugs to their targeting site. The antitumor activity in vitro and in vivo was evaluated to access the efficacy using PEG acidic-sensitive conjugate as tumor-targeting delivery system.

Evidence is provided that the conjugate could target tumor tissues, inhibit tumor growth, prolong the life of tumor-bearing mice and reduce cytotoxicity in normal tissues, as compared with using free DOX alone in vivo.

Results

Synthesis and characterization of DOX conjugates

The polymeric conjugates were synthesized as described above, shown in Fig. 1. For conjugation of DOX to PEG through hydrazone or amid bond, poly ethylene glycol was firstly oxide to poly ethylene glycol dioic acid catalyzed by KMnO4 at the terminal hydroxyl group. Then the hydrazone and amid conjugates were synthesized with help of catalyst, with yield of 82.5% and 87% respectively. The conjugates were purified by Sephadex G50 column eluted with water. The NMR spectrum (Fig. S1A) of PEG-hyd-DOX exhibited typical signals at chemical shifts of 7.1 ppm (2H, d, CH-2 and CH-4), 6.8 ppm (1H, d, CH-3), 5.3 ppm (1H, s, CH-1') and 4.08 ppm (3H, s, H3C-O-C-1), resulting from DOX, and at 3.61 ppm (PEG backbone); while the amid one exhibited typical signals at chemical shifts of 87.8 (2H, d, CH-2 and CH-4), 7.2 (1H, d, CH-3), 5.40 (1H, s, CH-1'), 4.10 (3H, s, H3C-O-C-1), 83.61 (PEG backbone). The DOX content of the hydrazone and amid conjugates were 10.64% and 3.9% (w/w) respectively, while the ideal conversion of DOX was about 15.34% and 16.16% for hydrazone and amid conjugates calculated by the molecule weight using the UV spectroscopic method (Figure S2), with absorbance of DOX at 480 nm. The purity of the two conjugates was all above 99% analyzed by HPLC, and typical chromatogram (Figure S1B) showed single sharp peak at 11.50 min (PEG-hyd-DOX) or 10.4 min (PEG-amid-DOX).

In vitro drug release

The release behavior of the two conjugates was carried out in different pHs, acetate buffer (pH 5.0) and phosphate buffer (pH 6.8 or 7.4) at 37°C. Fig. 2a revealed a significantly pH-dependent release profile of PEG-hyd-DOX, when at pH 7.4, a physiological condition, the polymeric conjugates were seemed stable, after 24 h incubation, only about 10% free DOX released. However, when at pH 6.8, an extracellular tumor condition [18], although mild acidic micro-environment occurred, still only about 20% cumulative DOX was determined after incubation. As turned to a modest acidic condition (pH 5.0), which was similar to intracellular acidic organelles pH value [19], the drug release became much fast with almost 80% cumulative DOX release after 24 h, presumably because of the pH-sensitive profile of the hydrazone linkage between DOX and polymer. On contrary, PEG-amid-DOX didn’t show the same pH-labile release behavior. Fig. 2b showed PEG-amid-DOX were insensitive to the pH value, the DOX release rate was nearly same at different pHs, after 24 h incubation, the cumulative release of DOX was only 50%, which were much lower than hydrazone conjugates released at pH 5.0, indicated amid ones might not release free DOX completely in tumor cells, led to a lower antitumor efficacy than hydrazone conjugates.

In vitro cellular sub-distribution

In this study, we have investigated DOX and its conjugates in tumor cells were investigated using fluorescence microscopy by labeling with nucleus selective dye (DAPI, blue) and intrinsic red fluorescence of DOX. All three tumor cells exposed to free DOX showed an obvious fluorescence signal in the nucleus (evidenced by purple dots in nucleus, a sign of co-localization of DOX with DAPI) and also non-specificity sub-cellular distribution in cytoplasm after 30 min, which might be explained that the mechanism of drug action for DOX is mainly by interaction with topoisomerase II existed in nucleus and its cellular uptake mechanism was basically via diffuse. However, red fluorescent dots of its amid-linkage polymeric conjugates were almost observed in the cytoplasm (red), indicated they might be locked in cytoplasm after uptake, so an effective dose couldn’t achieve at nucleus. Interestingly, the hydrazone linkage conjugates showed a much broad distribution either in cytoplasm (red) and nucleus (purple), confirmed the hydrolysis of hydrazone bond in tumor cells could release free drugs and help free DOX to distribute to its targeted sub-cellular region (nucleus) due to its pH-responsive profile, indicated the pH-triggered polymer via hydrazone bond could deliver drugs into tumor cell and then release the therapeutic agents to their targeting region as our designed (Fig. 3). And this phenomenon was in agreement with the results in the part of drug release experiment, such characteristic of drug distribution will be also tested and evidenced in the following experiments.

LC/MS/MS analysis for intracellular DOX accumulation

The intracellular DOX levels in different tumor cell lines were analyzed by LC/MS/MS. Briefly, quantitation of DOX was performed by multiple reactions monitoring of the deprotonated precursor ion and the related product ion, using the internal standard method with peak area ratio. Collision-induced dissociation was achieved using argon as the collision gas. A standard solution of 1 μg/ml DOX and resveratrol (internal standard) was applied to optimize the detection condition in the presence of the mobile phase (acetonitrile: water = 70:30, V/V). The compounds were separated on the C18 column using an isocratic mobile phase. The mass transitions used for DOX and resveratrol were m/z 542→395 (cone voltage, 120 eV; collision energy, 15 eV; dwell time, 400 ms) and 227→143 (cone voltage, 40 eV; collision energy, 30 eV; dwell time, 400 ms), respectively.

After drug treatment with three tumor cells as described above for 2, 4, 8 h respectively, the intracellular DOX levels were analyzed by HPLC-MS-MS (Fig. 4). The intracellular DOX levels of two polymeric conjugates in the three tumor cells were both time-dependent increased, while free DOX didn’t show this profile, which might be explained by the long circulation and slow-release profile of polymers. Both two polymeric DOX conjugates could increase the intracellular accumulation of DOX, and PEG-hyd-DOX led to a higher intracellular content of DOX due to the acid-labile hydrazone bond after taken up by cells. Therefore, the pH-triggered conjugates were expected to take on enhanced tumor accumulation and result in improved antitumor activity in vivo experiments. Among those three tumor cells, MDA-MB-231 was given the highest response to the polymeric drugs, which might be most sensitive to the synthesized conjugates in vivo. As shown in
Fig. 4a, the intracellular DOX levels of two conjugates in MDA-MB-231 were not significantly higher than DOX at first 2 h, consistent with their slow-released mechanism [20]. As incubation time goes by, the difference of intracellular DOX levels between polymeric conjugates and free DOX became obvious (p < 0.05 or 0.01), indicated an effective toxicity and therapeutic efficacy of our polymer needing much more treatment time. After 8 h incubation, the hydrazone treated group was 2.5 times higher than free DOX (p < 0.01) and 1.8 times higher than amid conjugate (p < 0.05), meant an obvious high accumulation of free DOX intracellular, and a mighty good biological activity of anticancer. Intracellular drug amount in MCF-7 cell was shown in Fig. 5b; it took on a similar trend as in MDA-MB-231 cell, after 2 h treatment, there was no statistic improvement of cellular uptake by two DOX-conjugates; when treated after 4 h, both two polymer groups accumulated higher amount of DOX in cell than free DOX (p<0.05), however, the two conjugates made almost same performance (no statistical difference). Only after 8 h incubation,

![Figure 1. Synthetic schemes of (a) PEG-hyd-DOX and (b) PEG-ami-DOX.](doi:10.1371/journal.pone.0044116.g001)

![Figure 2. In vitro cumulative DOX release.](a) PEG-hyd-DOX and (b) PEG-ami-DOX at 37°C at different pHs (pH was 5.0, 6.8 and 7.4 respectively) which were analyzed by HPLC. (n = 4, mean ± SD).](doi:10.1371/journal.pone.0044116.g002)
Antitumor Effect of DOX Conjugate
PEG-hyd-DOX could give a final significant difference compared with amid conjugate (p<0.05). When treated in HepG2 cell (Fig. 4c), the conjugates also showed a time dependent manner, and PEG-hyd-DOX showed the best response in drug cumulative among those three drugs, which could be 2.4 and 3 times higher than PEG-ami-DOX and DOX after 8 h incubation (p<0.05 or 0.01), similar with treatment on MDA-MB-231 and MCF-7 cells as described above, the two polymeric conjugates also didn’t show an prominent performance at the beginning of the incubation time (2 h), their slow-released profile still was the explanation.

**In vitro cytotoxicity**

From the above three different experiments, we found a common action on such drug release and distribution in tumor cell line, according to our original designing that hydrazone conjugates released much more free DOX than amid conjugates in the tumoral condition, and we will test the following hypothesis if such divergence will result in the different antitumor efficacy in *in vitro*. The cytotoxic activity of PEG-hyd-DOX against MCF-7, MDA-MB-231 and HepG2 cells was determined using an MTT assay which was summarized in Table 1. PEG-hyd-DOX exhibited more toxicity than free DOX in growth inhibition of three tumor cells, while MDA-MB-231 cell was most sensitive, consistent to the results of LC/MS/MS analysis. The IC50 value of DOX against MCF-7, MDA-MB-231 and HepG2 cells were 1.15, 2.3, 1.9 times higher than PEG-hyd-DOX respectively. Although the intracellular drug accumulation of PEG-ami-DOX was higher than free DOX, but cytotoxicity of PEG-ami-DOX was lower than both DOX and PEG-hyd-DOX. In addition, the IC50 values of PEG-ami-DOX was 2.1, 4.3 and 2.6 times higher than PEG-hyd-DOX in MCF-7, MDA-MD-231 and HepG2 cells, respectively. The obvious difference in cytotoxicity among those three formulations indicated that high intracellular concentration may not always bring good performance in biological activity, an effective drug accumulation in site of action (with regard to DOX, nucleus is action region) must be most important.

**In vivo antitumor activity**

Based on our *in vitro* results and the clinical use of DOX, the *in vivo* experiments were evaluated by subcutaneously xenografting SCID mice with the human breast carcinoma cell line MDA-MB-231 cell. PEG-hyd-DOX showed improved antitumor efficacy, lower toxicity, as measured in term of life span, tumor growth inhibition and body weight change, compared with free DOX.

Even given the same dose (5 mg/kg DOX equivalent), the tumor growth inhibition effect of PEG-hyd-DOX was better than that of free DOX at days 14, 21 and 28 after first drug treatment, as judged by the tumor volume (Fig. 5a). The antitumor activity took on a dose-dependent manner and showed a significantly difference between PEG-hyd-DOX (10, 15 mg/kg DOX equivalent) and DOX (5 mg/kg) 28 days later after therapy (p<0.05 or 0.01). Early in the treatment (days 7), the antitumor efficacy of PEG-hyd-DOX was not as good as DOX. This might be caused by the slow-released profile and intracellular uptake mode of polymer conjugate compared with that of free DOX, which was consistent with *in vitro* results.

Body weight change is a useful indicator of the systemic toxicity of the conjugates reference [21]. The body weight change curve showed that animals treated with PEG-hyd-DOX at three different doses gained weight steadily, however the body weight change was independent of dose. Conversely, mice treated with free DOX showed an initial decrease in body weight until day 6 and then a gradual weight gain; however they did not achieve similar level of weight gain as compared with the DOX conjugates treatment groups (Fig. 5b). These results showed that PEG-hyd-DOX could make effect without weight loss, which is a common side-effect in chemotherapy, suggested that a higher dose of DOX conjugate could potentially be used to give greater therapeutic efficacy, without serious side effects.

5, 10 and 15 mg/kg DOX conjugates groups (DOX equivalent) all could prolong the medium survival time to 26, 27 and 28 days respectively, as compared with mice treated with saline (13 days) or 5 mg/kg free DOX (24 days) (Fig. 5c).

**Pharmacokinetic and bio-distribution of PEG-hyd-DOX**

The tumor-targeting efficacy of the DOX conjugates were evaluated by detecting its pharmacokinetic process and bio-distribution by HPLC-MS-MS in blood and different organs of mice bearing MDA-MB-231 cells, respectively. Compared with free DOX (Fig. 6a), drug specific accumulation in tumor tissues was significantly increased following treatment with PEG-hyd-DOX (Fig. 6b), while the localization in other healthy organs, especially in the heart, was reduced obviously (p<0.05 or 0.001) (Fig. 6c). As we know, CHF (chronic heart failure) was the most
severe side-effect of DOX, so the lower distribution of DOX in heart by its conjugates will be beneficial in clinical trial, which indicated that the DOX conjugates showed well tumor-targeting activity without severe toxicity. It could also learned that at first 2 h after IV, the difference of DOX accumulation in tumor tissues between free DOX and its conjugates was not significantly (Fig. 6d) however, the accumulation of free DOX distributed to tumor by PEG-hyd-DOX showed peak concentration 8 h after iv; and then decreased to the initial levels after 24 h. On contrary, distribution of DOX formulation in healthy organs gave a decreasing trend accompany by time from 2 to 24 h. These results were consistent to the LC/MS/MS detection, identified PEG-hyd-DOX was a long-circulation profile and the DOX level was still much higher even after 24 h (p, 0.001, compared with DOX). The pharmacokinetic process of free dox and two conjugates in plasma were shown in Figure 7. The half-life of PEG-hyd-DOX and PEG-ami-DOX were 7.14 and 9.33 h, respectively. The results were consistent to our previous data and expected this PEG-DOX conjugate to be a potential carrier with tumor-targeting, enhanced antitumor efficacy, long-circulation, and low toxicity profiles.

**Discussion**

In the present study, we show this pH-triggered PEG-hyd-DOX conjugate could target DOX to tumor tissues and release free drugs by acidic tumor environment, which would be potent in antitumor drug delivery, and the primary findings regarding above effects are presented as follows: (1) PEG-hyd-DOX have the good anti-tumor effects in vitro and vivo; (2) PEG-hyd-DOX can targeted tumor cells through pH-triggered effects; (3) PEG-hyd-DOX have the less side effects on normal tissues; (4) PEG-hyd-DOX expressed the characteristic of slow released and long term circulation in vitro and vivo; (5) Hydrolysis of hydrazone bond in tumor cells could release free DOX to its target sub-cellular region (nucleus) as our designed. Thus, we conclude that of a novel pH-activated polymeric drug delivery system for doxorubicin was established successfully with good antitumor activity in vitro and in vivo.

During the synthetic route, the functionalized PEG was very vital for the following drug conjugation, so lots of groups have been introduced to the terminal of PEG [22]. In this paper, based on the structure of DOX, we made PEG carboxyl functionalized for next conjugation. Lots of strategies such as anhydride had been applied for carboxylation. However, they would change the basic structure of polymer and made these modified polymers become unstable, which might be hydrolysis before free drug released. So here we chose oxidation in presence of KMnO₄ to synthesis the

![Figure 5. Evaluation of in vivo anti-tumor activity of free DOX and PEG-hyd-DOX (5,10,15 mg/kg DOX. eq) on nude mice after s.c. human breast MDA-MB-231 cells. (a) tumor volume curve; (b) body weight changes; (c) survival curve. (n = 5, mean ± SD). doi:10.1371/journal.pone.0044116.g005](image)

| Drugs     | IC₅₀ (µM) | MCF-7  | MDA-MB-231 | HepG-2 |
|-----------|----------|--------|------------|--------|
| DOX       | 8.3±0.2  | 10.2±0.3| 14.3±0.4   |        |
| PEG-hyd-DOX | 7.2±1.1  | 4.4±0.6*| 7.6±0.9*   |        |
| PEG-ami-DOX| 15.2±1.5 | 18.8±0.7| 19.6±1.6   |        |

*Significant effects of factors on student’s t-test, p<0.05 compared with DOX. (n = 6, mean ± SD).

doii:10.1371/journal.pone.0044116.t001

Table 1. In vitro cytotoxicity of DOX and DOX-conjugates.
functional carboxylation PEG without backbone structure change, the reaction was easy to control and with a high yield of 80%.

pH-triggered drug delivery system has merged as an ideal carrier for anti-tumor agents, related to the acidic extracellular microenvironment in tumor tissues and some acidic organelles like lysosome and endosome. In our study, we synthesized a pH-sensitive DOX conjugate via a chemical linkage by hydrazone, and confirmed its profile by release behavior in vitro. From the results we learned that our conjugate was much acid-sensitive at pH 5.0 than 6.8, meant it might be an intracellular pH-triggered carrier. This characteristics attracted great interest in DOX delivery to tumor cells, after vein injection the polymeric conjugates will stay stable during blood circulation at physiological condition, resulted in a low systemic toxicity; once achieved and uptake by tumor cells, there will be a burst release of DOX for the acidic environment of lysosome-endosome, exhibiting a high intracellular concentration of DOX and obviously improved antitumor efficacy. This kind of carriers could be stable until uptake by tumor cells, made few DOX released before arrived at target region, led to low toxicity to normal cells.

DOX is positive for its free amid group with lone pair electrons, once entered the tumor cells, the DOX-conjugates, for its high molecule, would be first distributed in lysosome-endosome and be locked for the electrostatic attraction, if the drugs couldn’t escape, they might lose their activity eventually [9]. However, PEG-hyd-DOX could change this embarrassment by their pH-labile

**Figure 6.** Bio-distribution and accumulation of free DOX and PEG-hyd-DOX (5,10,15 mg/kg DOX, eq) in tissues. (a) free DOX, (b) PEG-hyd-DOX; cumulative accumulation of DOX in (c) tumor and (d) heart assayed by LC/MS/MS. (n = 5, mean ± SD).
doi:10.1371/journal.pone.0044116.g006

**Figure 7.** Plasma concentration-time curves of DOX, PEG-ami-DOX and PEG-hyd-DOX after i.v. administration to female tumor-bearing mice at the same 5 mg/kg DOX dose. (n = 5, mean ± SD).
doi:10.1371/journal.pone.0044116.g007
hydrazone linkage, when the hydrolysis of hydrazone bond occurred at low pH conditions in lysosome-endosome, lots of proton were acquired accompany with chloride ion flowing into the cells, led to lysosome swelling, cracking and unlocking the drugs, which was called as proton sponge effect [23]. So the pH-triggered profile of PEG-hyd-DOX could let a burst release of DOX when acidic and made free DOX localized to nucleus by proton sponge effect. The fluorescence images convinced our hypothesis by the co-localization of red fluorescence (DOX) with DAPI in nucleus (purple), confirmed PEG-hyd-DOX could escape from acidic organelles and finally arrived at nucleus. However, PEG-ami-DOX didn’t show the stimuli sensitive behavior, so it would be locked in cytoplasm (localization of red fluorescence in cytoplasm), which might result in a low therapeutic efficacy. Such image data was not enough to evaluate the qualification level of DOX, and thus the intracellular accumulation of free DOX, PEG-ami-DOX and PEG-hyd-DOX were detected and evaluated using HPLC/MS/MS methods in the following experiments.

Because DOX was an intracellular chemotherapy agent, so the intracellular accumulation of DOX in tumor cells could be seemed as an effective dose in cytotoxicity [24]. We determined the intracellular accumulation by HPLC/MS/MS method, which testified as high sensitive, good accuracy and reproducibility. From the HPLC/MS/MS analysis, as for the pH-stimuli release profile, PEG-hyd-DOX showed a highest accumulation in all the three tumor cells than both PEG-ami-DOX and free drug. PEG-ami-DOX and PEG-hyd-DOX were released slowly which has been demonstrated in the section of drug released experiment, and thus, above two different methods revealed the common phenomenon that these two conjugates can be released slowly in tumor microenvironment as our original designed. Consistent to the in vitro release profile, PEG-hyd-DOX remain its structure when extracellular, once in tumor cells, this conjugate would become unstable and release free drugs due to its high sensitivity to low pH in lysosome-endosome. The high intracellular concentration of DOX might be a premise for good toxicity against tumor cells and enhanced anti-tumor activity in vivo, indicated our designed conjugate will be more toxic than free DOX. Meanwhile, PEG-ami-DOX performed well than free DOX, explained by the different uptake mode by tumor cells. Polymers were often taken into cells via endocytosis, whereas free DOX, a small molecule drug, would passively diffuse into intracellular regions freely and quickly. It could also be learned that the intracellular DOX accumulation by those high molecule conjugates was increased with incubation time, consistent to their slow-released profile and long-acting effect, which might be guidance in dosage regimen assessment.

Cytotoxicity is a directly index for anti-tumor activity evaluation [25]. Considered the mechanism of action of DOX, a high accumulation of DOX in tumor cells might relate to a well toxicity. As known from the HPLC/MS/MS analysis, both two conjugates showed high intracellular concentration than free DOX, but their toxicity was significant different. PEG-hyd-DOX performed much better in cell growth inhibition than amid conjugate. Even PEG-ami-DOX also gave a higher accumulation of DOX than free drug in tumor cells due to its different uptake mode; it still showed the least toxicity among those formulations. Without pH-stimuli profile, although free DOX released from PEG-ami-DOX, they would be locked in lysosome-endosome (red dots observed in cytoplasm) and couldn’t arrive to nucleus to take effect; However, PEG-hyd-DOX took on best toxicity illustrated by the enhanced accumulation of free DOX in tumor cells with help of pH-triggered profile and a following sub-distribution into nucleus by proton sponge effect. The good cytotoxicity of PEG-hyd-DOX further proved the effect of pH-stimuli in tumor therapy. These results indicated than an ideal drug carrier should combine three features: keep stable before targeting site; release free drug completely when necessary; help transporting free drug to targeting region if possible. Fortunately, PEG-hyd-DOX met all these demands, so it hoped to be potent in antitumor therapy.

The results of drug released have been showed that the release of PEG-ami-DOX was much lower than PEG-hyd-DOX in tumor environment, this was mainly due to the different sub-distribution of such conjugates in tumor cells. In addition, the intracellular accumulation of PEG-hyd-DOX and PEG-ami-DOX also expressed different manners in the same condition. This direct evidence explain the reason why PEG-hyd-DOX have the better anti-tumor effect and less side-effect than PEG-ami-DOX, and also agreed with our original designing ideas. And thus, PEG-hyd-DOX was selected as the good candidate for the evaluation of vivo antitumor activity. DOX concentration was detected by HPLC/MS/MS to reflect the release level of PEG-hyd-DOX which was designed to release slowly in tumor, and our results also showed that PEG-hyd-DOX gave a long-circulation profile and retained higher concentration in tumor tissues at 8 hours. And the PEG-hyd-DOX release also expressed the obvious time-dependant manner in vitro experiments. Combine above evidences, such slowly released characteristics will be the base for the long-acting anti-tumor effects and lower side-effects. For another, such slowly released action was related with the intracellular uptake mode of polymer conjugate which often taken into cells via endocytosis, but for free DOX, will passively diffuse into intracellular regions freely and quickly due to its small molecule weight.

Based on our results from vivo antitumor activity, there are no significant difference in therapeutic effects, such as tumor volume, of different dose group before 28 days of the first injection, but the difference were clearly among these three dose groups after 28 days of the first injection. In the higher dose groups (10 mg/kg, 15 mg/kg), the tumor volume were lower than other two groups (p<0.05 or 0.01, Figure S3). And combined the results in vitro, both evidence showed the therapeutic effects of PEG-hyd-DOX with time-dependant manner. In addition, the body weight changes which reflect the toxicity of conjugates was independent of different dose, and demonstrated the steady and less toxicity of PEG-hyd-DOX in vivo. Furthermore, the data of mice survival also supported that PEG-hyd-DOX of each dose group can prolong the medium time differently after 28 days of the first injection (data not shown).

Following the in vitro results, we investigated the in vivo antitumor activity of PEG-hyd-DOX evaluated by tumor volume, weight change and survival time. A smaller tumor volume is the tumor activity of PEG-hyd-DOX evaluated by tumor volume, weight change and survival time. A smaller tumor volume is the
however, their in vivo antitumor activity was not good or they didn’t perform tumor-targeting profile as expected, which was primarily caused by their instability during blood circulation. With pH-sensitive release profile via hydrazone bond, PEG-hyd-DOX could stay stable till to tumor tissue, made their tumor targeting possible. The tumor targeting activity meant our designed conjugate could be specific target to tumor tissue and made a high effective dose, might lead to good therapeutic efficacy and low toxicity. PEG-hyd-DOX was an intracellular pH-triggered conjugate; its antitumor efficacy depended on high intracellular concentration of free drugs in target region. As described in vitro results before, once uptake by tumor cell, free drug released from the conjugate immediately and escaped from cytoplasm to nucleus to take effect. So the pH-stimuli profile was crucial for either tumor-targeting or antitumor efficacy in vivo. All these in vivo data indicated PEG-hyd-DOX would be a potential drug delivery system for chemotherapy agents.

The preparation and evaluation of a DOX conjugate, PEG-hyd-DOX, via a hydrazone linkage is described. This DOX conjugate showed pH-triggered release, higher cellular accumulation of DOX, and a higher cytotoxicity in vitro. This pH-sensitive conjugate could first distribute to cytoplasm and then made a burst release and unlock DOX from the cytoplasm to nucleus due to its pH-labile profile. Consistent with these results, PEG-hyd-DOX was more effective in tumor therapy than was free DOX and demonstrated good tumor targeting in vivo. These results indicate that this DOX conjugate shows good antitumor activity with less systemic side effects.

Materials and Methods

Ethics Statement

All procedures had the approval of the Animal Ethics Committee of the Fourth Military Medical University.

Materials

PEG (MW 6000), doxorubicin hydrochloride (DOX.HCl) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). 1-ethyl-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDCI) was obtained from Fluka (Sigma-Aldrich, St. Louis, MO); t-butyl carbazate was purchased from Alfa Aesar (Ward Hill, MA). All other chemicals were analytical grade without further purification. The cell lines HepG-2 (human hepatocellular liver carcinoma), MCF-7 and MDA-MB-231 (breast carcinoma) were obtained from Institute of Biochemistry and Cell Biology, Chinese Academy of Science. The severe combined immune deficient mice (SCID) were obtained from experimental animal center of the Fourth Military Medicinal University.

Synthesis of two PEG-DOX conjugates

The synthesis of PEG-hyd-DOX was achieved in three steps (Fig. 1). Briefly, polyethylene glycol was oxidized to polyethylene glycol dioic acid and obtain terminal carboxylic acid functional groups. Next, t-butyl carbazate (BOC-hydrazide) was conjugated to the modified polymer in the presence of EDCI and TEA (triethylamine) yielding PEG-Hyd-BOC (PEG dihydrazide with BOC protected). The BOC protective group was removed with HCl in ethyl acetate to obtain PEG-Hyd (PEG dihydrazide). DOX was then conjugated to PEG-Hyd, via a hydrazone bond, at the C13 carbonyl group of DOX by reaction with trifluoroacetic acid in methanol for 12 h.

PEG-ami-DOX was synthesized via amid bond for control. Briefly, PEG was firstly functionalized as described above, and then DOX was conjugated to the modified polymer (polyethylene glycol dioic acid) via amid bond at its free amino group with the presence of TEA and catalyzed by EDCI in DCM (Dichloromethane) for overnight.

Characterization of the conjugates

The two synthesized conjugates were characterized by 1H NMR spectroscopy (INOVA-400 MHz, Varian USA), using CDC13 as solvent. The DOX content were determined by UV spectroscopy at 480 nm immediately after hydrolysis of the conjugate in 1 M HCl at 85°C for 15 min, followed by neutralization. The purity of the conjugate was evaluated by RP-HPLC and the chromatographic separation was performed on a Waters symmetry C18 column (250×4.6 mm, 50 μm; Waters Corporation, Milford, MA, USA) with an isocratic mobile phase of acetonitrile/0.1% aqueous acetic acid (70/30, V/V) at a flow rate of 1 ml/min on Waters (Waters, MA, USA) 2695 HPLC system.

In vitro release of DOX from PEG-hyd-DOX conjugate

The release of DOX from the PEG-hyd-DOX or PEG-ami-DOX in vitro was performed at pH 5.0, 6.8 and 7.4 to investigate the drug release and acid sensitivity characteristics. 20 μg/mL PEG-hyd-DOX and PEG-ami-DOX conjugates (measured as DOX equivalent) were dissolved in acetate buffer saline (pH 5.0), phosphate buffer (pH 6.8 and 7.4) and incubated with gentle shaking in water bath at 37°C. At predetermined intervals (0.5, 1, 2, 4, 6, 8, 12 and 24 h), 20 μL samples were removed and replaced with an equal volume of buffer. The amount of released DOX was determined by HPLC method as described above.

Cell culture conditions

MCF-7, MDA-MB-231 and HepG2 cells were grown in DMEM (high glucose) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 5 μg/mL insulin (Sigma, St. Louis, MO), 100 μg/mL penicillin, 100 μg/mL streptomycin and 25 μg/mL amphotericin B (Invitrogen, Carlsbad, CA). Cultures were maintained in a humidified atmosphere of 5% CO2 at 37°C. The cells were subcultured at 80% confluence in 75-cm2 tissue culture flasks. For all experiments, 96-well or 24-well plates were inoculated with aliquots of cells removed from the flasks by brief treatment with 0.25% (v/v) trypsin (Invitrogen, Carlsbad, CA) and allowed to grow for 24 h for later drug treatment.

Cellular sub-distribution of PEG-hyd-DOX conjugate

Cellular sub-distribution of free DOX and its PEG conjugates were studied using a fluorescence microscope (Nikon DS-5M-Uliti Japan) to observe the influence of designed delivery system on intracellular distribution of DOX. Cells were seeded into 24-well plates at a cell density of 1×105 cells/mL. After 24 h, 20 μM free DOX or DOX conjugates (measured as free DOX equivalent, drugs were all dissolved in serum free medium with DMEM less than 0.1% when necessary) were added and incubated for 30 min at 37°C. After drug treatment, the medium was discarded; cells were rinsed three times with PBS, and then treated by 1 μg/mL DAPI for nuclei staining for 10 min, rinsed with PBS for three times and finally fixed with 4% paraformaldehyde for 10 min and observed using the intrinsic fluorescence of DOX by fluorescence microscope.
In vivo cytotoxicity

The tetrazolium dye (MTT) assay was performed to determine the cytotoxicity of free DOX and its conjugates in MCF-7, MDA-MB-231 and HepG2 cells based on a previously described method with minor modifications [17]. In brief, 200 μL aliquots of each type of cell suspension (1×10⁴ cells), harvested during a logarithmic growth phase, were pipetted into 96-well round-bottomed plates (Corning Costar, Corning, NY). Each plate was incubated with various concentrations of free DOX or its conjugates for 72 h at 37°C in a humidified atmosphere of 5% CO₂. Control cells received an equivalent volume of fresh medium. The MTT assay was performed, and the percentage of viable cells was determined. The absorbance of alive cell in each well was measured at 570 nm using a CODA Automated EIA Analyzer (Bio-Rad Laboratories, Hercules, CA).

Based on these measurements, the half-maximal inhibitory concentrations (IC₅₀), i.e., the amount of DOX needed to inhibit cell growth by 50%, were calculated for free DOX and its conjugates. A decrease in the IC₅₀ value indicates an increase in drug toxicity. The cell inhibition rate was calculated from the absorbance reading of the wells using the following formula:

\[
\text{Cell inhibition rate} = \frac{1 - (\text{absorbance of sample})}{(\text{absorbance of control})} \times 100
\]

Inhibition of tumor growth in vivo

PEG-hyd-DOX conjugate was used to treat SCID mice bearing MDA-MB-231 breast tumor cells. Female tumor-bearing mice were chosen and divided into different groups at random. Mice were inoculated subcutaneously with 1×10⁶ cells in a volume of 0.2 ml serum-free medium. When the tumor was large enough to be palpable (tumor volume = 50 mm²), the mice were treated once with DOX or its conjugate at a fixed dosage by tail vein injection and then were treated a second time 7 days later. The mice were observed every 3 days to monitor weight change as a sign of drug toxicity. The therapeutic efficacy was evaluated by tumor size and survival time. Survival time was assessed by a survival curve, and tumor size was measured every 3 days and calculated with the formula below:

\[
\text{Tumor volume} = \frac{1}{2} \times LW^2
\]

where L and W are the length and width of the tumor, respectively.

Pharmacokinetic and bio-distribution of PEG-hyd-DOX conjugate

DOX and its conjugate were administered to female tumor-bearing mice by tail vein injection to examine their plasma concentration and tissues distribution. After injection the mice were sacrificed, and the blood (at time of 0.08, 0.17, 0.5, 1, 2, 4, 8, 12, 24 h) and organs (tumor, heart, liver, spleen, lung, and kidney at fixed time intervals of 2, 8 and 24 h) were collected. Tissues were weighed and mixed with acetonitrile (with 0.1 ml of 50 ng/ml resveratrol added as an internal standard) and then homogenized. The sample of blood and homogenate from the different tissues were centrifuged at 3000× g for 10 min, and the supernatants were collected and analyzed for DOX contents by HPLC/MS/MS.

Statistical analysis

All experiments were performed in quadruplicate. The results are expressed as the mean ± SD from four to six independent measurements. Statistical analysis was performed as a one-way analysis of variance (ANOVA), and comparisons among groups were performed using an independent sample t-test.

Supporting Information

Figure S1 Characterization of synthesized conjugates. ¹H NMR spectra of (a) PEG-hyd-DOX in CDCl₃ and (b) PEG-ami-DOX CDCl₃; HPLC chromatogram for purity of (c) PEG-hyd-DOX and (d) PEG-ami-DOX. (EPS)

Figure S2 Particle size distribution of synthesized conjugates. The mean particle size which was measured by Zetasizer Nano instrument were 140 and 160 nm for PEG-ami-DOX (a) and PEG-hyd-DOX (b), respectively. (EPS)

Figure S3 Evaluation of in vivo anti-tumor activity of free DOX and PEG-hyd-DOX (5,10,15 mg/kg DOX. eq) on nude mice after s.c. human breast MDA-MB-231 cells (between 14 to 20 days). (EPS)

Author Contributions

Conceived and designed the experiments: MH SZ QM. Analyzed the data: MH ZT. Wrote the paper: MH ZT. Synthesized the conjugates: MH. Participated in cell experiments: BZ ZT HC. Performed the animal experiments: JW XL HX.

References

1. Lacroux L, Commo F, Soria JC (2008) Gene expression profiling of non-small-cell lung cancer. Expert Rev Mol Diagn 8:167–178.

2. Cuong NV, Jiang JL, Li YL, Chen JR, Jwo SC, et al. (2011) Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of
Multiple Administration of Micelle on the Suppression of Human Breast Cancer. Cancers 3(1):61–78.

3. Hu FQ, Liu LN, Du YZ, Yuan H (2009) Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 30(36):6955–63.

4. Ko JY, Park K, Kim QS, Kim MS, Ham JK, et al. (2007) Tumoral acidic extra-cellular pH targeting of pH-responsive MPEG-poly (β-amino ester) block copolymer micelles for cancer therapy. J Control Release 123:194–15.

5. Zhu S, Hong M, Tang G, Qian L, Lin J, et al. (2010) Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31(6):1390–71.

6. Murakami T, Sawada H, Tamura G, Yudasaka M, Iijima S, et al. (2008) Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine 3:453–463.

7. Liao D, Liu Z, Wrasidlo W, Chen T, Lao Y, et al. (2011) Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine 7(6):665–73.

8. Chen CH, Liu DZ, Fang HW, Liang HJ, Yang TS, et al. (2008) Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer. Biosci Biotechnol Biochem 72:1506–1509.

9. Gettinger S (2008) Targeted therapy in advanced non-small-cell lung cancer. Semin Respir Crit Care Med 29:298–310.

10. Kakinoki A, Kaneo Y, Ikeda Y, Tanaka T, Fujita K (2008) Synthesis of poly(vinyl alcohol)-doxorubicin conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release. Biol Pharm Bull 31(1):103–10.

11. Xiong XB, Ma Z, Lai R, Lavasanifar A (2010) The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 31(4):757–68.

12. Chen W, Meng F, Cheng R, Zhong Z (2010) pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 142(1):40–46.

13. Kotsakis A, Georgoulas V (2010) Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 11(14):2363–2389.

14. Pao W, Chmielecki J (2010) Rational, biologically based treated treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774.

15. Cheng C, Wei H, Zhu J, Zhang C, Cheng H, et al. (2008) Functionalized thermoresponsive micelles self-assembled from biotin-PEG-b-P(NIPAAm-co-HMAAm)-b-PMMA for tumor cell target. Bioconjug Chem 19:1194–1201.

16. Denmeade SR, Nagy A, Gao J (1998) Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 58:2537–2540.

17. Huan M, Zhou S, Teng Z, Zhang B, Liu X, et al. (2009) Conjugation with a-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin. Bioorg Med Chem Lett 19:2579–2584.

18. Lee AL, Yong W, Cheng HY, Pervaiz S, Yang YY (2009) The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30:919–27.

19. Leroux J, Roux E, Garrec D, Hang IC, Drummond DC (2001) Nisopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release 72:71–84.

20. Lin J, Lin S, Zhu J, Chen T, Cai C, et al. (2009) Drug releasing behaviour of hybrid micelles containing polypeptide triblock copolymer. Biomaterials 30:108–17.

21. Kukowska-Latallo JF, Candido KA, Cao Z, Nagavekar SS, Majoros IJ, et al. (2005) Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer. Cancer Res 65:5317–24.

22. Fox ME, Guillaudeu S, Fievet JM, Jerger K, Macaraeg N, et al. (2009) Synthesis and in vivo antitumor efficacy of PEGylated poly(lysine) dendrimer-camptothecin conjugates. Mol Pharm. 6(5):1562–72.

23. Sethuraman VA, Na K, Bae YH (2006) pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules 7:64–70.

24. Ryu BY, Sohn JS, Hess M, Choi JK, Choi SK, Choo JK, et al. (2008) Synthesis and anticancer efficacy of rapid hydrolysed water-soluble paclitaxel prodrugs. J Biomater Sci Polym Ed 19:311–324.

25. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, et al. (2007) Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 122:365–374.

26. Tae-Hee Kim, Christopher WM, Wayne RG, Suzie H (2010) The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 31:7386–7397.